Relationship Between Great Toe Strength And Symptoms of Chemotherapy-Induced Peripheral Neuropathy (CIPN)

Eligibility Criteria for Chemotherapy-Induced Peripheral Neuropathy (CIPN) group:

Inclusion Criteria:

• At least 18 years of old with the ability to independently raise and low (extend orflex) the great toe

• Able to consent and complete questionnaires in English independently and have normalto corrected vision (self-reported)

• Within 3 - 6 months of starting chemotherapy and a confirmed diagnosis of CIPN usingthe current clinical reference standard of Nerve conduction study.

Exclusion Criteria:

• Comorbidities including but not limited to diabetes, arthritis, hypertension,thyroid disease, and heart disease, . that have been reported to be associated withthe incidence of peripheral neuropathy and/or progression of CIPN.

• Toe deformities or impairments not caused by CIPN (including but not limited tohallux valgus/varus, hallux limitus, hallux rigidus, hammer toe deformity, claw toe,bunions, webbed toes)

• Self-reported impairment or impact on the strength of the foot, ankle, and/or greattoe due to past medical or surgical history.

Eligibility Criteria for Healthy Control group: The participants recruited for this group will be age- and sex- matched to the CIPN group

• Inclusion Criteria:

• At least 18 years of old with the ability to independently raise and low (extend orflex) the great toe

• Able to consent and complete questionnaires in English independently and have normalto corrected vision (self-reported)

• No known health conditions that have been reported to be associated with differentimpairements in mobility, balance, and muscle strength (particularly in the lowerextremity)